Institute of Pathology, University of Munich, Munich, Germany.
Department of Dermatology and Allergology, University of Munich, Munich, Germany.
Mod Pathol. 2014 Jan;27(1):19-29. doi: 10.1038/modpathol.2013.117. Epub 2013 Jun 28.
Adult-onset urticaria pigmentosa/mastocytosis in the skin almost always persists throughout life. The prevalence of systemic mastocytosis in such patients is not precisely known. Bone marrow biopsies from 59 patients with mastocytosis in the skin and all available skin biopsies (n=27) were subjected to a meticulous cytological, histological, immunohistochemical, and molecular analysis for the presence of WHO-defined diagnostic criteria for systemic mastocytosis: compact mast cell infiltrates (major criterion); atypical mast cell morphology, KIT D816V, abnormal expression of CD25 by mast cells, and serum tryptase levels >20 ng/ml (minor criteria). Systemic mastocytosis is diagnosed when the major diagnostic criterion plus one minor criterion or at least three minor criteria are fulfilled. Systemic mastocytosis was confirmed in 57 patients (97%) by the diagnosis of compact mast cell infiltrates plus at least one minor diagnostic criterion (n=42, 71%) or at least three minor diagnostic criteria (n=15, 25%). In two patients, only two minor diagnostic criteria were detectable, insufficient for the diagnosis of systemic mastocytosis. By the use of highly sensitive molecular methods, including the analysis of microdissected mast cells, KIT D816V was found in all 58 bone marrow biopsies investigated for it but only in 74% (20/27) of the skin biopsies. It is important to state that even in cases with insufficient diagnostic criteria for systemic mastocytosis, KIT D816V-positive mast cells were detected in the bone marrow. This study demonstrates, for the first time, that almost all patients with adult-onset mastocytosis in the skin, in fact, have systemic mastocytosis with cutaneous involvement.
成人获得性色素性荨麻疹/肥大细胞瘤在皮肤中几乎总是终生存在。此类患者的系统性肥大细胞瘤的患病率尚不清楚。对来自 59 例皮肤肥大细胞瘤患者的骨髓活检和所有可用的皮肤活检(n=27)进行了细致的细胞学、组织学、免疫组织化学和分子分析,以确定是否存在世界卫生组织定义的系统性肥大细胞瘤的诊断标准:致密肥大细胞浸润(主要标准);肥大细胞形态不典型、KIT D816V、肥大细胞 CD25 异常表达和血清胰蛋白酶水平>20ng/ml(次要标准)。当主要诊断标准加一个次要标准或至少三个次要标准时,即可诊断为系统性肥大细胞瘤。通过致密肥大细胞浸润加至少一个次要诊断标准(n=42,71%)或至少三个次要诊断标准(n=15,25%),确诊了 57 例(97%)患者的系统性肥大细胞瘤。在 2 例患者中,仅检测到两个次要诊断标准,不足以诊断系统性肥大细胞瘤。通过使用包括微切割肥大细胞分析在内的高度敏感的分子方法,在所有 58 例进行分析的骨髓活检中均发现了 KIT D816V,但仅在 74%(20/27)的皮肤活检中发现了 KIT D816V。重要的是要指出,即使在系统性肥大细胞瘤诊断标准不足的情况下,也可以在骨髓中检测到 KIT D816V 阳性的肥大细胞。这项研究首次表明,实际上,所有患有成人获得性皮肤肥大细胞瘤的患者都患有伴有皮肤受累的系统性肥大细胞瘤。